Platelet P2Y12 Inhibitor in the Treatment and Prevention of Migraine: A Systematic Review and Meta-Analysis

Table 1

Demographic and clinical characteristics of included studies for migraine patients with or without PFO.

Study	Country	Design	Patients	Mean age (yr)	Treatments		Sample size	Dropouts	Efficacy results	Adverse events
					Intervention	Control
Chambers et al. [9]	UK	Parallel RCT	Migraineurs with four to 15 headache days per 28-day month	45	Clopidogrel 75 mg/d for three months	Placebo once daily for three months	35 vs. 36	4 vs. 5	The number of headache days fell by 1.9 on clopidogrel and 1.8 on placebo (0.02, CI: -2.07 to 2.12)	Total: 17 vs. 14; Bruises: 5 vs. 3; Nosebleed: 3 vs. 1
Reisman et al. [10]	USA	Open-label single-arm feasibility trial	Patients ≥6 monthly MHA days with PFO	36.3	Ticagrelor 90 mg twice/d for 28 days	NA	40	2	17 (43%) participants were ticagrelor responders. No patient had complete relief	Total: 13; Bruises: 5
Sommer et al. [11]	USA	Open-label single-arm feasibility trial	Patients with MHA and PFO	37.9	Clopidogrel 75 mg/d for 1-3 months. Nonresponders were offered prasugrel	NA	136	1	90 (66%) patients were thienopyridines responders. 56 (70%) of clopidogrel had complete or near complete relief	Mild bleeding: 3; Cutaneous bruising: 20; Fatigue: <5%
Spencer et al. [12]	USA	Open-label single-arm feasibility trial	Patients with severe MHA and PFO	32.3	Clopidogrel 75 mg/d for 4 weeks	NA	15	1	13 (87%) patients were responders. 9 (60%) had complete relief	Allergic symptoms: 1

RCT: randomized controlled trial; NA: not applicable; PFO: patent foramen ovale; MHA: migraine headache.